An internal standard for the quantification of mifepristone
Related Products
Unlabeled Version(s)
10006317Mifepristone
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Mifepristone-d3

Item No. 10010660

Technical Information
Formal Name
11β-[4-(dimethylamino-d3)phenyl]-17β-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
Molecular Formula
C29H32D3NO2
Formula Weight
Purity
≥99% deuterated forms (d1-d3)
Formulation
A crystalline solid
Chloroform: SolubleMethanol: Soluble
SMILES
O=C1CCC(C(CC2)=C1)=C([C@]2([H])[C@@](CC[C@]3(C#CC)O)([H])[C@]3(C)C4)[C@H]4C5=CC=C(N(C([2H])([2H])[2H])C)C=C5
InChi Code
InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1/i3D3
InChi Key
VKHAHZOOUSRJNA-PBWRPEOTSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Mifepristone-d3 is intended for use as an internal standard for the quantification of mifepristone (Item No. 10006317) by GC- or LC-MS. Mifepristone is an antagonist of glucocorticoid, progesterone, and androgen receptors (Kis = 0.1, 0.64, and 0.65 nM, respectively).1,2,3 It is selective for these receptors over the mineralocorticoid receptor (MR), estrogen receptor α (ERα), and ERβ (Kis = 640, >200, and >750 nM, respectively).1 In cell-based assays, mifepristone inhibits alkaline phosphatase activity stimulated by the progesterone receptor agonist R5020 as well as reporter transcription stimulated by either dexamethasone (Item No. 11015) or R5020 (IC50s = 7, 5.9, and 1.3 nM, respectively).3 It also inhibits synthetic androgen R1881-stimulated reporter transcription in a concentration-dependent manner.2 Mifepristone (10 µM) inhibits growth of 4-OHT-resistant MCF-7 breast cancer cells in vitro.4 It also inhibits tumor growth in an SKOV3 ovarian cancer nude mouse xenograft model when administered at doses of 0.5 or 1 mg per day.5 Formulations containing mifepristone have been used for the induction of medical abortions.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. von Gerldern, T.W., Tu, N., Kym, P.R., et alLiver-selective glucocorticoid antagonists: A novel treatment for type 2 diabetes. J. Med. Chem. 47(17), 4213-4230 (2004).

    2. Song, L.-N., Coghlan, M.J., and Gelmann, E.P. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol. Endocrinol. 18(1), 70-85 (2004).

    3. Attardi, B.J., Burgenson, J., Hild, S.A., et alIn vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J. Steroid Biochem. Mol. Biol. 88(3), 277-288 (2004).

    4. Gaddy, V.T., Barrett, J.T., Delk, J.N., et alMifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin. Cancer Res. 10, 5215-5225 (2004).

    5. Goyeneche, A.A., Carón, R.W., and Telleria, C.M. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin. Cancer Res. 13(11), 3370-3379 (2007).